山香圆叶治疗糖尿病并发症的化学成分及治疗潜力

Shanxiangyuanye (Turpiniae Folium) for diabetic complications: chemical constituents and therapeutic potential

  • 摘要:
    目的 采用液相色谱-串联质谱(LC-MS/MS)技术分析山香圆叶的化学成分,并评价其与糖尿病并发症相关的抗氧化、降糖及抗糖基化活性。
    方法 对山香圆叶经水提醇沉后所得的上清液(TFS)进行 LC-MS/MS 分析。通过三种实验方法评价TFS的体外抗氧化活性:1,1-二苯基-2-苦基肼(DPPH)自由基清除实验、2,2’-联氮-双-3-乙基苯并噻唑啉-6-磺酸(ABTS+)自由基阳离子脱色实验和羟基(·OH)自由基清除实验;通过 α-葡萄糖苷酶抑制实验分析其体外降糖潜力;随后建立牛血清白蛋白(BSA)-果糖(Fru)、BSA-丙酮醛(MGO)、BSA-乙二醛(GO)及 D-精氨酸(Arg)-MGO四种体外模型研究其抗糖基化活性来重点观察TFS的抑制效果。此外,采用BSA-Fru模型在37 °C孵育7天后,对糖基化溶液中的果糖胺、蛋白质羰基、巯基及β-淀粉样蛋白的含量进行定量分析。
    结果 通过正、负离子模式下的LC-MS/MS分析,从TFS中鉴定出750种化学成分,主要包括有机酸、氨基酸及其衍生物。体外活性研究表明,TFS表现出显著的自由基清除能力,对DPPH、ABTS+和·OH自由基的半抑制浓度(IC50)分别为0.47、1.56和0.36 mg/mL。在降糖活性方面,TFS以剂量依赖方式抑制α-葡萄糖苷酶活性(IC50 = 0.21 mg/mL),效果与临床药物阿卡波糖相当(IC50 = 0.23 mg/mL)。值得注意的是,TFS可干预糖基化过程:在BSA-Fru、BSA-MGO/GO和Arg-MGO模型中的IC50值分别为0.22、1.91 – 4.96和4.09 mg/mL,其中在BSA-Fru模型中抑制效果最为突出。此外,尽管TFS在糖化过程中可能无法有效保护BSA中的巯基或减少巯基氧化,但能显著降低果糖胺水平(呈剂量依赖性)、减少β-淀粉样蛋白的形成并抑制蛋白质羰基化(P < 0.000 1)。
    结论 本研究结果表明,TFS化学成分复杂,具有显著的抗氧化、降糖和抗糖基化活性,为其作为预防糖尿病及并发症的天然辅助剂提供了科学依据,并在功能食品开发和辅助抗糖尿病治疗中奠定了坚实基础。

     

    Abstract:
    Objective To analyze the chemical constituents of Shanxiangyuanye (Turpiniae Folium) through liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and to evaluate their anti-oxidant, hypoglycemic, and anti-glycation activities related to diabetic complications.
    Methods The supernatant of Shanxiangyuanye (Turpiniae Folium) (TFS), obtained following water extraction and alcohol precipitation, was analyzed by LC-MS/MS. Antioxidant activity of TFS in vitro was evaluated using three experimental approaches: the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay, the 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS+) radical cation decolorization assay, and the hydroxyl (·OH) radical scavenging assay. To comprehensively evaluate hypoglycemic potential, α-glucosidase inhibition was measured to analyze in vitro hypoglycemic activity. Subsequently, in vitro models were developed to examine anti-glycation activity through the bovine serum albumin (BSA)-fructose (Fru), BSA-methylglyoxal (MGO), BSA-glyoxal (GO), and D-arginine (Arg)-MGO systems, with particular attention to the inhibitory effects of TFS. Furthermore, the concentrations of fructosamine, protein carbonyls, sulfhydryl groups, and β-amyloid in the glycation solution were quantified using the BSA-Fru model following 7-d of incubation at 37 °C.
    Results Using LC-MS/MS analysis in both positive and negative ion modes, we identified 750 chemical components in TFS, primarily including organic acids, amino acids, and their derivatives. In vitro activity studies demonstrated that TFS exhibited remarkable free radical scavenging capacity, with half-maximal inhibitory concentrations (IC50) of 0.47, 1.56, and 0.36 mg/mL against DPPH, ABTS+, and ·OH radicals, respectively. Regarding hypoglycemic activity, TFS dose-dependently inhibited α-glucosidase activity (IC50 = 0.21 mg/mL), displaying comparable efficacy to the clinical drug acarbose (IC50 = 0.23 mg/mL). Notably, TFS intervened in the glycation process: IC50 values were 0.22, 1.91 – 4.96, and 4.09 mg/mL in the BSA-Fru, BSA-MGO/GO, and Arg-MGO models, respectively, with the most prominent inhibitory effects observed in the BSA-Fru model. Furthermore, although TFS may not effectively preserve thiol groups in BSA or reduce thiol oxidation during glycation, it significantly reduces fructosamine levels (in a dose-dependent manner), decreases β-amyloid formation, and inhibits protein carbonylation (P < 0.000 1).
    Conclusion The findings demonstrate that TFS exhibits a complex chemical composition with potent antioxidant, hypoglycemic, and anti-glycation activities. These results provide compelling scientific evidence supporting TFS’s potential as a natural adjuvant for diabetes prevention and complication management, while laying a solid foundation for its applications in functional food development and adjunctive antidiabetic therapeutics.

     

/

返回文章
返回